RTW Investments has taken a significant step by initiating a new stake in Apellis Pharmaceuticals (APLS), acquiring 7,666,764 shares valued at approximately $192.59 million in the fourth quarter of 2025. This move marks a notable entry for RTW, as Apellis now represents 1.93% of its reportable assets under management, indicating a strategic diversification into a commercial-stage biotech firm.
Despite Apellis’s recent struggles, with shares down 29% over the past year compared to a 15% rise in the S&P 500, the company has demonstrated solid revenue generation, reporting around $689 million last year. This performance was largely driven by its flagship therapy, pegcetacoplan, which alone contributed $587 million. The investment suggests a shift towards more stable revenue sources amidst a portfolio that primarily focuses on high-growth biotech opportunities.
For market professionals, RTW’s investment in Apellis highlights a potential strategy to balance high-risk biotech positions with established revenue streams, making it a noteworthy development for those tracking sector dynamics and investment trends in the biotech space.
Source: fool.com